169 related articles for article (PubMed ID: 17457056)
21. Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses.
Ishii H; Vecchione A; Fong LY; Zanesi N; Trapasso F; Furukawa Y; Baffa R; Huebner K; Croce CM
Curr Gene Ther; 2004 Mar; 4(1):53-63. PubMed ID: 15032614
[TBL] [Abstract][Full Text] [Related]
22. Exome-wide single-base substitutions in tissues and derived cell lines of the constitutive Fhit knockout mouse.
Paisie CA; Schrock MS; Karras JR; Zhang J; Miuma S; Ouda IM; Waters CE; Saldivar JC; Druck T; Huebner K
Cancer Sci; 2016 Apr; 107(4):528-35. PubMed ID: 26782170
[TBL] [Abstract][Full Text] [Related]
23. Fhit deficiency-induced global genome instability promotes mutation and clonal expansion.
Miuma S; Saldivar JC; Karras JR; Waters CE; Paisie CA; Wang Y; Jin V; Sun J; Druck T; Zhang J; Huebner K
PLoS One; 2013; 8(11):e80730. PubMed ID: 24244712
[TBL] [Abstract][Full Text] [Related]
24. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.
Ishii H; Dumon KR; Vecchione A; Fong LY; Baffa R; Huebner K; Croce CM
JAMA; 2001 Nov; 286(19):2441-9. PubMed ID: 11712940
[TBL] [Abstract][Full Text] [Related]
25. Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX.
Ishii H; Mimori K; Vecchione A; Sutheesophon K; Fujiwara T; Mori M; Furukawa Y
Biochem Biophys Res Commun; 2004 Apr; 316(4):1088-93. PubMed ID: 15044096
[TBL] [Abstract][Full Text] [Related]
26. microRNA-143 protects cells from DNA damage-induced killing by downregulating FHIT expression.
Lin YX; Yu F; Gao N; Sheng JP; Qiu JZ; Hu BC
Cancer Biother Radiopharm; 2011 Jun; 26(3):365-72. PubMed ID: 21711110
[TBL] [Abstract][Full Text] [Related]
27. The FHIT gene product: tumor suppressor and genome "caretaker".
Waters CE; Saldivar JC; Hosseini SA; Huebner K
Cell Mol Life Sci; 2014 Dec; 71(23):4577-87. PubMed ID: 25283145
[TBL] [Abstract][Full Text] [Related]
28. Molecular parameters of genome instability: roles of fragile genes at common fragile sites.
Pichiorri F; Ishii H; Okumura H; Trapasso F; Wang Y; Huebner K
J Cell Biochem; 2008 Aug; 104(5):1525-33. PubMed ID: 18393361
[TBL] [Abstract][Full Text] [Related]
29. A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention.
Zanesi N; Pekarsky Y; Croce CM
Mutat Res; 2005 Dec; 591(1-2):103-9. PubMed ID: 16085127
[TBL] [Abstract][Full Text] [Related]
30. Protein expression profiling identifies cyclophilin A as a molecular target in Fhit-mediated tumor suppression.
Semba S; Huebner K
Mol Cancer Res; 2006 Aug; 4(8):529-38. PubMed ID: 16885564
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms shaping the mutational landscape of the FRA3B/FHIT-deficient cancer genome.
Saldivar JC; Park D
Genes Chromosomes Cancer; 2019 May; 58(5):317-323. PubMed ID: 30242938
[TBL] [Abstract][Full Text] [Related]
32. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR.
Thavathiru E; Ludes-Meyers JH; MacLeod MC; Aldaz CM
Mol Carcinog; 2005 Nov; 44(3):174-82. PubMed ID: 16187332
[TBL] [Abstract][Full Text] [Related]
33. ATR preferentially interacts with common fragile site FRA3B and the binding requires its kinase activity in response to aphidicolin treatment.
Wan C; Kulkarni A; Wang YH
Mutat Res; 2010 Apr; 686(1-2):39-46. PubMed ID: 20060399
[TBL] [Abstract][Full Text] [Related]
34. Hits, Fhits and Nits: beyond enzymatic function.
Huebner K; Saldivar JC; Sun J; Shibata H; Druck T
Adv Enzyme Regul; 2011; 51(1):208-17. PubMed ID: 21035495
[TBL] [Abstract][Full Text] [Related]
35. Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic.
Matsuyama A; Shiraishi T; Trapasso F; Kuroki T; Alder H; Mori M; Huebner K; Croce CM
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):14988-93. PubMed ID: 14630947
[TBL] [Abstract][Full Text] [Related]
36. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
37. Biological functions of mammalian Nit1, the counterpart of the invertebrate NitFhit Rosetta stone protein, a possible tumor suppressor.
Semba S; Han SY; Qin HR; McCorkell KA; Iliopoulos D; Pekarsky Y; Druck T; Trapasso F; Croce CM; Huebner K
J Biol Chem; 2006 Sep; 281(38):28244-53. PubMed ID: 16864578
[TBL] [Abstract][Full Text] [Related]
38. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
39. Pathology and biology associated with the fragile FHIT gene and gene product.
Saldivar JC; Shibata H; Huebner K
J Cell Biochem; 2010 Apr; 109(5):858-65. PubMed ID: 20082323
[TBL] [Abstract][Full Text] [Related]
40. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim H; Kim CH
Oncotarget; 2017 May; 8(19):31923-31937. PubMed ID: 28404875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
